Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. - Wikidata - wikimedia - TriplyDB

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.

http://www.wikidata.org/entity/Q37195095

about

Pharmacological treatments for fatigue associated with palliative care Safety of off-label erythropoiesis-stimulating agents for critically ill patients Erythropoietin or darbepoetin for patients with cancer Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.Total synthesis of glycosylated proteins S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data [Hematopoietic growth factors. Possibilities and limitations].Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines.Effect of erythropoietin levels on mortality in old age: the Leiden 85-plus Study Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies - results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers.Mapping the homodimer interface of an optimized, artificial, transmembrane protein activator of the human erythropoietin receptor.Epoetin beta for the treatment of chemotherapy-induced anemia: an update.Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation.Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer Patient Blood Management: A Patient-Orientated Approach to Blood Replacement with the Goal of Reducing Anemia, Blood Loss and the Need for Blood Transfusion in Elective Surgery Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agents Contrasting effect of recombinant human erythropoietin on breast cancer cell response to cisplatin induced cytotoxicity Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece.Anemia in elderly people: Risk marker or risk factor?Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events.Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells.A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.Anemia in cancer.Management of anemia in cancer patients.

P2860

Q24187756-A250A784-526F-4D24-A85D-ACF839DE7A27 Q24200811-78909E8F-0780-4E0E-B0D7-BE39552259D6 Q24202335-635DCCD5-EC8A-4EB5-A9A0-112CA2A80816 Q24306910-747818D9-C6EE-4250-8C0D-C700AB04A942 Q26865984-92CE0B9C-9737-4DD9-91CF-63D47CF636D5 Q27343148-6D2BE91E-36E8-4068-9F09-517CAA4C815E Q28083496-5FB34623-CEBE-491B-AFB7-2454495D6763 Q28554256-0C398D1A-653B-4675-BDC9-09FF06AE446E Q30803363-D842B8B7-C57D-45AE-B825-86D8AC03CEBA Q33390111-E507431A-F60D-4759-8188-4D6483EF31C1 Q33630871-0BB34FD3-6F1C-49E9-BCC2-C9233855DCE9 Q34042768-267699DD-13E2-48F9-BC7C-FE6429CD768C Q34131083-9B2B3DD6-5413-4325-B931-2AE54132C8E3 Q34399172-27841761-C4F2-4C71-A060-A5298C12F6C8 Q34403856-E04A7598-2FB8-4821-A3EE-7D95D844C94F Q34554073-09C8A197-CB1B-4AEF-84A3-7BF03C9786BA Q34635638-442B9C92-BA4D-43A2-958D-0C6C28673531 Q34810071-A0DE404D-638B-4224-9D51-30BC9E4B194F Q35161709-713C5E2C-C5B5-4D30-BDE4-F8281AA2C7BE Q35168681-271DC927-1BD2-45E4-8D22-96914BF70BEF Q35620681-B3CD42AE-A73B-445B-ABC1-B5576EF6EBD5 Q35633372-B0ACD048-BB78-4FBA-88D8-FB33B21166EF Q35642998-F50679F5-71F0-4729-A6C6-71C83B2AFEE5 Q35858979-9FED8027-7BDA-4150-A77E-E526E4E8C43D Q35949310-FD4A7A2C-1A78-4ECB-BCDE-9708F01F9B33 Q35998221-43E89683-A0D8-4882-8A60-6BCE69F75066 Q36095172-E2023C5A-1365-4E1E-9923-BAB9EFD0F4C8 Q36322416-59968AEF-194A-41DA-9309-FAE0924E1196 Q36801561-1EA17832-6DA0-4A02-82E8-94CBE4CBE53B Q37021210-1E407DC3-CD55-46A9-9139-791403388740 Q37028832-F29F002D-1AB4-4A64-93ED-501D9EB80FF6 Q37280472-A671763A-9509-4DC2-92F3-C2AD2C11AEFB Q37438625-F0CFBC48-FBC4-41CD-8BD1-5AD0C559CDC6 Q37481924-67735EBE-27B6-41D1-9EB1-16421D50E7E5 Q37564558-4E0FD6C2-45C6-452D-B183-610357FB1009 Q37610106-5D485950-5DC3-410C-9660-A461A659B72F Q37626692-76114E5B-19A7-44B8-9029-703393C13D68 Q37766575-86343618-EB1D-406B-80F9-F0CF9E40F66B Q37799923-B54A5743-09CA-468D-BCAC-F0415084C880 Q37861195-A048C51A-4DA4-452E-87C4-C9DFBA26F1E5

P2860

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.

http://www.wikidata.org/entity/Q37195095

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Benefits and harms of erythrop ...... ed to cancer: a meta-analysis.

@en

Benefits and harms of erythrop ...... ed to cancer: a meta-analysis.

@nl

type

label

Benefits and harms of erythrop ...... ed to cancer: a meta-analysis.

@en

Benefits and harms of erythrop ...... ed to cancer: a meta-analysis.

@nl

prefLabel

Benefits and harms of erythrop ...... ed to cancer: a meta-analysis.

@en

Benefits and harms of erythrop ...... ed to cancer: a meta-analysis.

@nl

P1433

Q37195095-E6273A46-FAB4-41C9-B4A1-00FA8FDC6D4E

P1476

Q37195095-C1D7766B-E6DA-4F21-B05F-C9EF27DD0473

P2093

Q37195095-7BF2671D-76E4-492A-A84A-794CC30097BC

Q37195095-9EEA5B03-FE16-40B6-8233-43F1377A9AC2

Q37195095-A61E95D7-A382-41D8-9EB0-CCA8F84FE2DB

Q37195095-A6EA78C6-9E2A-45E5-81FD-0B0B27A3DD0B

Q37195095-C376B843-6759-4CB9-8990-A42A5FD4DF5A

Q37195095-FC60CA81-3A17-4FA4-8192-CD9F3CDE43C6

P2860

Q37195095-18D6B31F-6750-474C-8D3E-15AE9AA28F94

Q37195095-1AF5F88F-3296-4C65-8A24-8BD534BD724E

Q37195095-1B8E7610-B199-4402-9FB3-C785940BCFF3

Q37195095-1DCCDB55-EC6B-48F2-96C7-9BDF1D6570B6

Q37195095-1FC8C9BD-7A16-4F65-8A42-CE16C34A32FD

Q37195095-27FC3FE2-1DE2-407D-924C-DCA0B5B6AE26

Q37195095-2AD32D65-B04B-4EF4-9D22-1043B045EE06

Q37195095-3D688467-616B-47CE-A61D-4487AB4EB559

Q37195095-3E7AF4E0-C3B6-4C7A-8050-395FE13F2CA4

Q37195095-42E0B3E3-874C-41B7-89D6-5BEB6A637C9B

P304

Q37195095-4F36C939-99C6-4F4D-9107-75E2335D6924

P31

Q37195095-13eb14a8-812b-426c-be2c-7b817724bc45

Q37195095-4764472B-105B-47B0-B56F-BFDD1EF7681E

P356

Q37195095-4A4397E6-1A0A-4888-8581-F120FACAA4DD

P407

Q37195095-41CBAAF4-AA57-4D83-B909-A6A9FB1F1764

P433

Q37195095-AAB92B1B-9BAE-4B05-AF08-111705A9C4C4

P478

Q37195095-478A9233-2E6C-4E0A-9A35-D783A693EF31

P50

Q37195095-07A7AE59-BF9E-4FF7-990C-A0A618491DEE

Q37195095-E1974AAE-A2B7-4DB6-8CE0-1DBF83C94344

P577

Q37195095-6D66F71B-8584-4713-939F-BE48494565B2

P5875

Q37195095-65A173C2-14DB-4070-A0AB-C9EBBB899E75

P698

Q37195095-16EF4DB7-4091-4227-A43A-01B2C921E586

P921

Q37195095-D6F0E259-ED16-423F-A915-8291988C2CC6

P932

Q37195095-1421D71D-1553-4DB0-AECF-D75D23E661B4

P356

P1433

Canadian Medical Association Journal

P1476

Benefits and harms of erythrop ...... ed to cancer: a meta-analysis.

@en

P2093

Anita Lloyd

http://www.w3.org/2001/XMLSchema#string

Braden Manns

http://www.w3.org/2001/XMLSchema#string

Brenda Hemmelgarn

http://www.w3.org/2001/XMLSchema#string

M Neil Reaume

http://www.w3.org/2001/XMLSchema#string

Scott Klarenbach

http://www.w3.org/2001/XMLSchema#string

Tony Reiman

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Measuring inconsistency in meta-analyses

Quantifying heterogeneity in a meta-analysis

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

Meta-analysis in clinical trials

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

How should meta-regression analyses be undertaken and interpreted?

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.

P304

E62-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.090470

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

180

http://www.w3.org/2001/XMLSchema#string

P50

Marcello Tonelli

P577

2009-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24394278

http://www.w3.org/2001/XMLSchema#string

P698

19407261

http://www.w3.org/2001/XMLSchema#string

P921

P932

2683210

http://www.w3.org/2001/XMLSchema#string